Related Party Transactions - Additional Information (Detail) - USD ($)		3 Months Ended			6 Months Ended
	Jun. 29, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Feb. 29, 2016
Related Party Transaction [Line Items]
Collaboration revenue - related party		$ 1,216,000		$ 5,263,000	$ 2,709,000	$ 9,911,000
Proceeds from issuance of common stock	$ 27,525,000
Common stock at a purchase price	$ 3.15	$ 0.001			$ 0.001		$ 0.001
Common stock, shares issued	8,738,243
Nestle Health Science [Member]
Related Party Transaction [Line Items]
Collaboration revenue - related party		$ (197,000)		5,263,000	$ 528,000	9,911,000
Deferred revenue		97,200,000			97,200,000		$ 97,728,000	$ 120,000,000
Payments under agreements with related party			$ 0		0
Due from related party for the reimbursement of development costs		0			0
Nestle Health Science [Member] | 2021 License Agreement [Member]
Related Party Transaction [Line Items]
Collaboration revenue - related party		1,413,000			2,181,000
Deferred revenue		3,908,000			3,908,000		6,089,000
Payments under agreements with related party		0			0
Due from related party for the reimbursement of development costs		0			$ 0
Flagship Pioneering [Member] | Sublease Agreement [Member]
Related Party Transaction [Line Items]
Lessee, term of operating sublease, description					The term of the sublease agreement commenced in July 2019 and ended in November 2021.
Sub lease commencement date			2019-07
Cash received from related party transaction				464,000		925,000
Flagship Pioneering [Member] | Sublease Agreement [Member] | Other Income [Member]
Related Party Transaction [Line Items]
Sublease income				$ 464,000		$ 925,000
Accrued Expenses and Other Liabilities [Member] | Nestle Health Science [Member] | 2021 License Agreement [Member]
Related Party Transaction [Line Items]
Transaction price allocated under collaborative arrangement		$ 33,062,000			$ 33,062,000		$ 31,683,000